2. Signaling Pathways
  3. GPCR/G Protein
  4. Angiotensin Receptor
  5. AT1 Receptor Isoform
  6. AT1 Receptor Antagonist

AT1 Receptor Antagonist

AT1 Receptor Antagonists (27):

Cat. No. Product Name Effect Purity
  • HY-17512
    Losartan
    		Antagonist 99.67%
    Losartan is an angiotensin II receptor antagonist, competing with the binding of angiotensin II to AT1 receptors with IC50 of 20 nM.
  • HY-13955
    Telmisartan
    		Antagonist 99.81%
    Telmisartan is a potent, long lasting antagonist of angiotensin II type 1 receptor (AT1), selectively inhibiting the binding of 125I-AngII to AT1 receptors with IC50 of 9.2 nM.
  • HY-18204
    Valsartan
    		Antagonist 99.87%
    Valsartan (CGP 48933) is an angiotensin II receptor antagonist and has the potential for high blood pressure and heart failure research.
  • HY-105440
    LY 301875
    		Antagonist
    LY 301875 is a potent and orally active angiotensin II receptor type 1 (AT1) antagonist with a pKB value of 9.6.
  • HY-117805
    UR-7247
    		Antagonist
    UR-7247 is a potent and orally active angiotensin II AT1 receptor antagonist. UR-7247 decreases arterial pressure and increases renal blood flow.
  • HY-19202
    rac-Olodanrigan
    		Antagonist
    rac-Olodanrigan (rac-EMA401; EMA400) is a racemic mixture of the S-enantiomer (EMA401; HY-13106) and R-enantiomer (EMA402). rac-Olodanrigan is a potent and selective AT2 receptor antagonist with IC50s of 75.2 nM and 2918 nM for AT2R and AT1R, respectively. rac-Olodanrigan evokes dose-dependent relief of mechanical allodynia in the ipsilateral hind paws of rats with a chronic constriction injury (CCI) of the sciatic nerve.
  • HY-12403
    Talfirastide
    		Antagonist 99.91%
    Angiotensin 1-7 (Ang-(1-7)) is an endogenous heptapeptide from the renin-angiotensin system (RAS) with a cardioprotective role due to its anti-inflammatory and anti-fibrotic activities in cardiac cells. Angiotensin 1-7 inhibits purified canine ACE activity (IC50=0.65 μM). Angiotensin 1-7 acts as a local synergistic modulator of kinin-induced vasodilation by inhibiting ACE and releasing nitric oxide. Angiotensin 1-7 blocks Ang II-induced smooth muscle cell proliferation and hypertrophy and shows antiangiogenic and growth-inhibitory effects on the endothelium. Angiotensin 1-7 shows anti-inflammatory activity .
  • HY-P0216
    A 779
    		Antagonist 98.59%
    A 779 is a specific antagonist of G-protein coupled receptor (Mas receptor), which is an Ang1-7 receptor distinct from the classical AngII.
  • HY-17512A
    Losartan potassium
    		Antagonist 99.91%
    Losartan potassium (DuP-753 potassium) is an angiotensin II receptor type 1 (AT1) antagonist, competing with the binding of angiotensin II to AT1 with an IC50 of 20 nM.
  • HY-17004
    Olmesartan
    		Antagonist 99.91%
    Olmesartan (RNH-6270) is an angiotensin II receptor (AT1R) antagonist used to treat high blood pressure.
  • HY-14914
    Azilsartan
    		Antagonist 99.51%
    Azilsartan (TAK-536) is an orally active, potent, selective and specific angiotensin II type 1 receptor (AT1) antagonist. Azilsartan induces ROS formation and apoptosis in HepG2 cells. Azilsartan shows neuroprotective and anticancer activity. Azilsartan can be used for hypertension and stroke research.
  • HY-14736
    Azilsartan medoxomil
    		Antagonist 99.60%
    Azilsartan medoxomil (TAK 491) is an orally administered angiotensin II receptor type 1 antagonist with IC50 of 0.62 nM, which used in the treatment of adults with essential hypertension.
  • HY-12405
    CGP-42112
    		Antagonist 99.23%
    CGP-42112 (CGP-42112A) is a potent Angiotensin-II subtype 2 receptor(AT2 R) agonist.
  • HY-B0780
    Fimasartan
    		Antagonist 98.55%
    Fimasartan (BRA-657) is an orally effective angiotensin receptor AT1 non-peptide antagonist. Fimasartan has antihypertensive effects. Fimasartan improves neuroinflammation and brain injury mediated by NLRP3 inflammatome after intracerebral hemorrhage, and has neuroprotective effect. Fimasartan inhibits the expression of inducible nitric oxide synthase through the inactivation of NF-κB and activator protein-1.
  • HY-12403A
    Talfirastide acetate
    		Antagonist 99.87%
    Angiotensin 1-7 (Ang-(1-7)) acetate is an endogenous heptapeptide from the renin-angiotensin system (RAS) with a cardioprotective role due to its anti-inflammatory and anti-fibrotic activities in cardiac cells. Angiotensin 1-7 acetate inhibits purified canine ACE activity (IC50=0.65 μM). Angiotensin 1-7 acetate acts as a local synergistic modulator of kinin-induced vasodilation by inhibiting ACE and releasing nitric oxide. Angiotensin 1-7 acetate blocks Ang II-induced smooth muscle cell proliferation and hypertrophy and shows antiangiogenic and growth-inhibitory effects on the endothelium.
  • HY-A0250
    Tasosartan
    		Antagonist 99.07%
    Tasosartan is a long-acting angiotensin II (AngII) receptor antagonist.
  • HY-19732
    BIBS 39
    		Antagonist 99.70%
    BIBS 39 is a new nonpeptide angiotensin II (AII) receptor antagonist.
  • HY-131276
    Olmesartan lactone impurity
    		Antagonist 99.27%
    Olmesartan lactone impurity is a cyclic ester impurity of Olmesartan. Olmesartan is an angiotensin II receptor (AT1R) antagonist and has the potential for high blood pressure study.
  • HY-18204S
    Valsartan-d9
    		Antagonist 99.33%
    Valsartan-d9 is deuterium labeled valsartan. Valsartan is an angiotensin II receptor antagonist and has the potential for high blood pressure and heart failure research[1].
  • HY-131278
    Olmesartan methyl ester
    		Antagonist
    Olmesartan methyl ester is an intermediate in the synthesis of Olmesartan medoxomil. Olmesartan medoxomil is a potent and selective angiotensin AT1 receptor antagonist with IC50 of 66.2 μM.